AXIS Clinicals announces successful completion of 23rd US FDA Audit
AXIS Clinicals Limited announces today that it has successfully completed US FDA Audit without any observations or 483s.
- (1888PressRelease) June 08, 2018 - Ahmedabad, INDIA – AXIS Clinicals Limited, leading Clinical Research Organization (CRO), announces today that it has successfully completed US FDA Audit without any observations or 483s.
The latest surprise audit by US FDA with NO 483’s is a resounding success for AXIS Clinicals. Having a successful US FDA audit, along with the many successful regulatory audits UK-MHRA, France-AFSSAPS / ANSM, Brazil-ANVISA, WHO, GCC, MHSD RoK, Thai GLP, Turkey MOH, NABL and CDSCO for CPU set up in INDIA as well as Clinical Trials conducted at various sites; demonstrates that AXIS Clinicals has attained the Quality Standards laid by the international regulatory bodies and will ensure the ‘Best Quality with Highest Standards - All The Time.’
AXIS Clinicals has completed 2700+ studies, complying with all the norms laid by major regulatory agencies.
About AXIS Clinicals
AXIS Clinicals Limited is the preferred valued partner for clinical studies in India (Hyderabad & Ahmedabad), USA, and Mexico (ranging from BioEquivalence and Phase II to IV Clinical Trials, Clinical Data Management). AXIS Clinicals is committed to serve the biopharmaceutical industry with the global standards and most accurate results.
For further information contact AXIS Clinicals Business Development Team at BD ( @ ) axisclinicals dot com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam